• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国消灭脊髓灰质炎

Eradication of poliomyelitis in the United States.

作者信息

Nathanson N

出版信息

Rev Infect Dis. 1982 Sep-Oct;4(5):940-50. doi: 10.1093/clinids/4.5.940.

DOI:10.1093/clinids/4.5.940
PMID:7146731
Abstract

Mass immunization with oral poliovirus vaccine (OPV) was begun in the United States in 1963, and the least natural outbreak of poliomyelitis occurred in 1972. Since immunization programs fail to reach the total population, eradication has been achieved in the presence of a residual susceptible population of at least 5% (2-5 million children under the age of 15 years). It is proposed that the fade-out of wild polioviruses is explained by their disappearance during the winter, a low point in the yearly cycle of the virus. In the post-eradication era, the continued presence of millions of susceptible children and adults presents a constant potential hazard. Every effort should be made to maintain maximal levels of immunization with oral poliovirus vaccine and to prevent the reintroduction of wild polioviruses into the United States.

摘要

1963年美国开始大规模口服脊髓灰质炎疫苗(OPV)免疫接种,1972年出现了最少的自然脊髓灰质炎疫情。由于免疫规划未能覆盖全体人口,因此在至少5%(200 - 500万15岁以下儿童)的残余易感人群存在的情况下仍实现了根除。有人提出,野生脊髓灰质炎病毒的消失是因为它们在冬季(病毒年度周期的低点)消失。在根除后的时代,数百万易感儿童和成人的持续存在构成了持续的潜在风险。应尽一切努力维持口服脊髓灰质炎疫苗的最高免疫接种水平,并防止野生脊髓灰质炎病毒重新传入美国。

相似文献

1
Eradication of poliomyelitis in the United States.美国消灭脊髓灰质炎
Rev Infect Dis. 1982 Sep-Oct;4(5):940-50. doi: 10.1093/clinids/4.5.940.
2
Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses.关于脊髓灰质炎病毒所致麻痹性脊髓灰质炎快速消除及最终全球根除的观点
Eur J Epidemiol. 1991 Mar;7(2):95-120. doi: 10.1007/BF00237353.
3
Prospects for the eradication of infectious diseases.根除传染病的前景。
Rev Infect Dis. 1984 May-Jun;6(3):405-11. doi: 10.1093/clinids/6.3.405.
4
Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.消灭脊灰:全世界的儿科医生如何助力永远终结这种致残疾病
Pediatrics. 2015 Jan;135(1):196-202. doi: 10.1542/peds.2014-3163.
5
Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).美国的脊髓灰质炎预防:采用先接种灭活脊髓灰质炎病毒疫苗后接种口服脊髓灰质炎病毒疫苗的序贯接种程序。免疫实践咨询委员会(ACIP)的建议
MMWR Recomm Rep. 1997 Jan 24;46(RR-3):1-25.
6
Anomalous observations on IPV and OPV vaccination.关于脊灰灭活疫苗(IPV)和口服脊髓灰质炎疫苗(OPV)接种的异常观察结果。
Dev Biol (Basel). 2001;105:197-208.
7
Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.脊髓灰质炎疫苗。全球根除脊髓灰质炎的进展以及美国常规免疫接种建议的变化。
Pediatr Clin North Am. 2000 Apr;47(2):287-308. doi: 10.1016/s0031-3955(05)70208-x.
8
Poliomyelitis: eradication in sight.脊髓灰质炎:消灭在望。
Epidemiol Infect. 1992 Feb;108(1):1-18. doi: 10.1017/s0950268800049451.
9
Epidemiologic aspects of poliomyelitis eradication.根除脊髓灰质炎的流行病学方面
Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S308-12. doi: 10.1093/clinids/6.supplement_2.s308.
10
Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine.在世界不同地区使用口服脊髓灰质炎疫苗消除脊髓灰质炎的策略。
Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S391-6. doi: 10.1093/clinids/6.supplement_2.s391.

引用本文的文献

1
Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review.疫苗的药物警戒:重要性、主要方面、前景与挑战——一篇叙述性综述
Pharmaceuticals (Basel). 2024 Jun 19;17(6):807. doi: 10.3390/ph17060807.
2
Incidence of Vaccine-Preventable Childhood Diseases in the European Union and in the European Free Trade Association Countries.欧盟及欧洲自由贸易联盟国家儿童疫苗可预防疾病的发病率。
Vaccines (Basel). 2021 Jul 17;9(7):796. doi: 10.3390/vaccines9070796.
3
Chapter 4 Picornavirus infections.第4章 小核糖核酸病毒感染
Perspect Med Virol. 1985;1:127-186. doi: 10.1016/S0168-7069(08)70012-0. Epub 2008 May 29.
4
Viral replicons as valuable tools for drug discovery.病毒复制子作为药物发现的有价值工具。
Drug Discov Today. 2020 Jun;25(6):1026-1033. doi: 10.1016/j.drudis.2020.03.010. Epub 2020 Apr 6.
5
Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015-2018.2015-2018 年美国急性弛缓性脊髓炎患者特征。
Emerg Infect Dis. 2020 Feb;26(2):212-9. doi: 10.3201/eid2602.191453.
6
Does Herd Immunity Exist in Aquatic Animals?水生动物中存在群体免疫吗?
Int J Mol Sci. 2016 Nov 15;17(11):1898. doi: 10.3390/ijms17111898.
7
Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.描述脊灰病毒的传播和演变:野病毒和疫苗相关脊灰病毒建模经验的启示。
Risk Anal. 2013 Apr;33(4):703-49. doi: 10.1111/risa.12044. Epub 2013 Mar 22.
8
Putting together the pieces of polio: how Dorothy Horstmann helped solve the puzzle.将小儿麻痹症的各个部分放在一起:多萝西·霍斯特曼如何帮助解决难题。
Yale J Biol Med. 2011 Jun;84(2):83-9.
9
From emergence to eradication: the epidemiology of poliomyelitis deconstructed.从出现到消灭:脊髓灰质炎的流行病学剖析。
Am J Epidemiol. 2010 Dec 1;172(11):1213-29. doi: 10.1093/aje/kwq320. Epub 2010 Oct 26.
10
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.对已获许可的病毒疫苗、其中一些安全性问题以及研究性病毒疫苗开发进展的综述。
J Infect. 2004 Oct;49(3):179-209. doi: 10.1016/j.jinf.2004.05.018.